 |
| Sir Michael Rawlins and Carlo Patrono |
These Awards, including the EACPT silver medal, were presented at an Awards Ceremony
the 11th EACPT Congress in Geneva, 28th - 31st August 2013 by EACPT co-founder Professor Folke Sjöqvist, and by Dr Marie Besson, co-leader of the 2011 EACPT Congress.
Carlo Patrono is Professor and Chair of the Department of Pharmacology at the Catholic University School of Medicine (UCSC) in Rome, Italy. He is also the Chairman of the Task Force on Antiplatelet Agents of the European Society of Cardiology.
Prof. Patrono’s main research interest is in the study of platelet
activation and inhibition in atherothrombosis. He pioneered development of
radioimmunoassays for measuring prostanoid and isoprostane biosynthesis in
health and disease. His research has characterized the human pharmacology of
aspirin as an inhibitor of platelet COX-1 and provided the basis for the
development of low-dose aspirin as an antithrombotic agent. During the past
decade Prof. Patrono has contributed to characterizing the human pharmacology of
COX-2 inhibitors and evaluating their cardiovascular effects in different
clinical settings.
For development of low-dose aspirin for the prevention of cardiovascular
disease, Professor Patrono was joint recipient with Garret FitzGerald in April
2013 from the Institut de France of the 500,000 euro 2013 Grand Prix
Scientifique, the world’s most prestigious prize for cardiovascular research.
He has also received the Alexander B. Gutman award from the Mount Sinai
School of Medicine, the Distinguished Award in Neuroscience from the Louisiana
State University, the 1998 International Aspirin® Award from Bayer AG, the 2007
John Vane Award from the William Harvey Research Institute of the University of
London, and the 2011 Outstanding Achievement Award of the Eicosanoid Research
Foundation.
 |
| Professor Sir Michael Rawlins |
Michael Rawlins was from 1999-2013 the first chairman of the National Institute for Health and Clinical Excellence (NICE), and from 1998-2008, Chairman of the
Advisory Council on the Misuse of Drugs. He was also Professor of Clinical
Pharmacology at the University of Newcastle upon Tyne from 1973 – 2006) and
from 1992-1998 Chairman of the UK Committee on the Safety of Medicines, which
advised UK government ministers on marketing authorization for new pharmaceuticals,
and on withdrawal of medicines in the event of safety concerns. He is currently
President of the Royal Society of Medicine and Chairman of the UK Biobank.
As Chairman of NICE, he led one of the world’s most important
healthcare organizations, which, based on clinical and cost-effectiveness,
guides the National Health Service on whether medicines and other health
technologies should be available to patients, and develops evidence-based clinical
guidelines for health professionals. Many countries have studied the work of NICE
and adopted its ideas and innovations.
Sir Michael’s outstanding scientific contributions have been recognised
by the award of numerous honours and distinctions, including his appointment as
Knight Bachelor in 1999 for “services to the improvement of patient protection
from the side effects of medicinal drugs”.
 |
| Jamie Coleman, Sir Michael Rawlins, Philip Routledge and Donald Singer |
The EACPT was founded 20 years ago and now includes all national organisations for clinical pharmacology in Europe. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.
Official EACPT journal: Clinical Therapeutics
Future EACPT Congresses and Summer Schools
2014 - 11th EACPT Summer School - Nijmegen: 5-8 July
2015 - 12th EACPT Congress - Madrid
2017 - 13th EACPT Congress - Prague
2019 - 14th EACPT Congress - Stockholm
